@epsteinpedia
CA:
AEb4NmMJF2x5kcp19M13RiXZuAGyajWSKLaioqBrpump
Document DOJ-OGR-00026019
AI Analysis
Summary: An email chain between the Chief Pharmacist and Supervisory Staff Attorney at MCC New York discusses an inmate's medication, confirming that the inmate has an active Vascepa prescription but no record of a back pain medication prescription. The attorneys had alleged the inmate was not receiving necessary medication.
Significance: This email chain reveals a potential issue with an inmate's access to medication, specifically Vascepa and back pain medication, and the communication between the prison's pharmacy and legal staff regarding the inmate's treatment.
Key Topics:
inmate medication
Vascepa prescription
back pain treatment
Key People:
- (b)(6); (b)(7)(C) - Chief Pharmacist at MCC New York
- (b)(6); (b)(7)(C) - Supervisory Staff Attorney at CLC New York
Full Text
Page 2250
Good Morning,
He has active refillable Rx-Vascepa which was dispensed on 7/17 for a 30 day supply..? We can place them on PL starting tomorrow. Vascepa is on order.
No rx for back pain on file.
Thank You,
(b)(6); (b)(7)(C)
PharmD, MS, BCACP
CAPT, U.S. Public Health Service
Chief Pharmacist
MCC New York
150 Park Row,
New York, NY 10007
(b)(6); (b)(7)(C)@bop.gov
Phone: (646) 836-(b)(6); (b)(7)(C)
Fax: (646) 836-7680
"This message is intended for official use and may contain SENSITIVE information. If this message contains SENSITIVE information, it should be properly delivered, labeled, stored, and disposed of according to policy."
Commissioned Corps of the United States Public Health Service - "Protecting, promoting, and advancing the health and safety of the Nation"
>> (b)(6); (b)(7)(C) 7/30/2019 7:48 AM >>>
Good morning all,
The above inmate's attorneys have recently alleged he is not receiving cholesterol or back pain medication. Please see him for these and other complaints.
Thank you,
(b)(6); (b)(7)(C)
(b)(6); (b)(7)(C)
Supervisory Staff Attorney
CLC New York
Metropolitan Correctional Center
150 Park Row
New York, New York 10007
p: (646)836-(b)(6); (b)(7)(C)
f: (646)836-7665
Page 12842
DOJ-OGR-00026019